Skip to main content
ZTS
NYSE Life Sciences

Zoetis Q3 10-Q: Revenue Down 1%, Net Income Down 18% to $591M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$83.475
Mkt Cap
$34.494B
52W Low
$68.77
52W High
$132.49
52W Position info
21% above low
Off High info
37% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ZTS sits 21% above its 52-week low of $68.77.

Summary

Zoetis' Q3 10-Q confirms revenue of $2.39 billion (down 1%) and net income of $591 million (down 18%), with a $78 million R&D impairment and $43 million of restructuring charges weighing on results amid a weak U.S. companion animal market.


Key Events · Earnings and Guidance · ZTS

  • Q3 Revenue Slips 1% to $2.39B

    Revenue fell to $2,391 million from $2,422 million, a 2% decline on an operational basis, as U.S. companion animal sales dropped 8% to $980 million.

  • Net Income Down 18% on Impairment

    Net income fell to $591 million ($1.44 per diluted share) from $721 million, hit by a $78 million in-process R&D impairment on PetMedix assets and $43 million of restructuring charges.

  • Restructuring Program Ramps Up

    Nine-month restructuring and acquisition-related costs reached $142 million, with $123 million of employee termination costs under a comprehensive cost and productivity program.

  • IRS Dispute Over $450M Adjustment

    The IRS proposed an additional tax liability of approximately $450 million, excluding interest and penalties, for the 2018 tax year; the matter is under appeal and the company disputes it.


Analysis · ZTS · Life Sciences

The full quarterly report confirms the headline weakness first disclosed in this morning's earnings release and fills in the detail behind it. U.S. companion animal revenue fell 8% to $980 million as dermatology faced heightened competition and generic pressure hit Convenia and Cerenia, while livestock grew 5%. A $78 million in-process R&D impairment on the PetMedix assets and $43 million of restructuring charges pushed net income down 18% to $591 million, or $1.44 per diluted share. Two overhangs sit alongside the operating miss: an IRS proposed adjustment of roughly $450 million for the 2018 tax year still under appeal, and an amended securities class action filed October 23, 2026 naming the CEO, former CFO and CCO over allegedly misleading companion animal demand statements. Cash generation remains solid at $1.88 billion for nine months, and the company bought back 17.7 million shares for $1.66 billion.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZTS was trading at $83.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $34.5B. The 52-week trading range was $68.77 to $132.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZTS - Latest Insights

ZTS
Nov 05, 2026, 1:15 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $83.15
Real-time Price: $80.90 info
Change: -$2.24 (-3%) info
Market Cap: $32.826B info
ZTS
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $88.78
Real-time Price: $80.90 info
Change: -$7.88 (-9%) info
Market Cap: $32.826B info
ZTS
Aug 13, 2026, 3:51 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $75.45
Real-time Price: $80.90 info
Change: +$5.45 (+7%) info
Market Cap: $32.826B info
ZTS
Aug 06, 2026, 2:32 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $77.03
Real-time Price: $80.90 info
Change: +$3.87 (+5%) info
Market Cap: $32.826B info
ZTS
Aug 06, 2026, 2:10 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $76.28
Real-time Price: $80.90 info
Change: +$4.63 (+6%) info
Market Cap: $32.826B info